COVAX Allocation Round 6 IAVG Vaccine Allocation Decision - 23 July 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COVAX Allocation Round 6
IAVG Vaccine Allocation Decision
23 July 2021Background
❑ Context for Round 6 & Vaccine Scope
❑ Humanitarian Buffer
❑ Dose Donations
❑ Participant Scope
❑ Detailed Participant Exclusion Report
Table of Contents
Round 6 Proposals
❑ Scenario 1 and 2:
❑ Descriptive Statistics Summary
❑ Overview Graphs
❑ Distribution Proposal & Shipment Considerations
❑ Conclusions & Signatures
Annex/Background
❑ Overview of Allocations to Date
❑ Overview of Dose Donations to Date
❑ Overview of COVAX Shipped/allocated doses vs total population coverage
*Please kindly note that the Round 6 VAD proposal is supplemented with a single accompanying spreadsheet: the Round 6 output from the Allocation Portal. In particular, two tabs on this
2
spreadsheet, Output and Exclusion report, outline which Participants are proposed to receive an allocation in this Round and which are not.Background
Context for COVAX Allocation Round 6 & Vaccine Scope
Minimum Shipment Size
Context for Round 6
Timing of Round 6 Product Name Minimum Shipment Size (doses)
• The timing of COVAX Allocation Rounds is triggered when supply of vaccines with Sinopharm BIBP • 1,200
global regulatory approval is confirmed for a defined period. Round 6 includes the • 20,400 for pop. over 1M
following two products:
• Beijing CNBG - BIBP-CorV (also known as “Sinopharm”) – EUL 07 May 2021
Sinovac • 1,200
• 20,400 for pop. over 1M
• Sinovac – CoronaVac (“Sinovac”) – EUL 01 June 2021.
• A status overview of COVID-19 vaccines in the WHO EUL evaluation process is
available here. Overview of Available Supply
• The COVAX Facility announced it had secured advance purchase agreements Product Name Total Supply (doses)
(APA) for the two products on 12 July 2021, with a portion available for immediate
delivery. Sinopharm BIBP 42,649,200
• Round 6 allocations are intended for delivery during Q3-2021, the Total Monthly
Sinovac 42,650,400
Supply Availability table on the right outlines the breakdown of available supply.
• Due to close timing between COVAX Allocation Rounds 5 and 6, the Facility will Humanitarian Buffer 14,700,400
ensure close communication with participants to confirm their ability to absorb
TOTAL 100,000,000
doses before they are shipped.
Round Supply Considerations Total Monthly Supply Availability
• Sinopharm BIBP has 2 different minimum shipment sizes for Participants with a
population above or below 1 million (see Minimum Shipment Size table above on Product Name July Aug Sept
the right).
Sinopharm BIBP 10M 20M 20M
• Details on the supply for the Humanitarian Buffer are outlined on the next slide.
Sinovac 5M 25M 20M
Information on supply availability was provided to the JAT by the COVAX Procurement Coordinator, UNICEF SD. 3Background
Humanitarian Buffer
Overall Humanitarian Buffer Allocation
Product Name Total Supply (doses)
Sinopharm BIBP 7,350,800
Sinovac 7,349,600
TOTAL 14,700,400
Proposed Allocation to the Humanitarian Buffer
Allocation of Doses to the COVAX Humanitarian Buffer
• The JAT proposes to allocate a total of 14.7M doses to the Humanitarian Buffer (for immediate approval by the Inter-Agency Standing
Committee). More information on how the Humanitarian Buffer is managed and governed may be accessed here.
• This sum is the total amount owed to the Buffer from COVAX Allocation Rounds 1-6, constituting 5% of available supply from the
COVAX APA-secured deals for each Round.
• From Rounds 1-5, a total of 9.7M doses were owed to the Buffer, yet none were available for use until Round 6.
• The number of applications to the Buffer are expected to rise as manufacturers waive indemnity and liability (I&L) requirements, which
to date include Sinopharm and Sinovac.
• Sinopharm and Sinovac are programmatically suitable products for use in humanitarian settings and have a fridge-temperature shelf
life of 12-24 months.
• Supply not used by the Buffer will be reallocated to Facility Participants to ensure that available doses do not go idle.
• The JAT will monitor closely the use of HB doses and applications across Q3 and will reallocate quickly to ensure this.
4Background
Round Context - Donations
Context for Round 6
Vaccine Donations to COVAX
• Following COVAX Allocation Round 5, several dose donations have been executed. This constituted a total of
8,756,720 doses of AZ vaccine, donated by France, Norway, Spain, Sweden and the United Kingdom.
• The increase in benefitting Participants’ percent total population coverage achieved through COVAX-secured
doses as a result of these donations is factored into this Allocation Round.
• Adjustments to the dose donations from the United States of America and from Japan have been processed in
the Allocation Portal in advance of running Allocation Round 6. While the adjustment to the dose donation from
Japan was minor, the donation from the USG increased by 25 million doses since the donation was originally
entered into the Portal before Round 5.
• Therefore, additional dose donations from Round 5 to Round 6 constitute a total of roughly 33.7 million doses.
• An aggregated overview of dose donations to date may be accessed on slides 18 and 19 in the Annex of this
PowerPoint.
5Snapshot
Scenario 1 vs. Scenario 2
Scenario 1 Scenario 2
Scenario Overview Scenario Overview
• Participants receiving allocations: 83 • Participants receiving allocations: 60
• Participants excluded: 79 • Participants excluded: 102
Scenario Issues Changes Made to Scenario 1
• Several Participants received only the Round minimum (i.e. • Round minimum set to 0
100,800 doses)
• Batch size for Sinopharm changed to 1,200
• Due to algorithm rule that Round minimum must be given to all
Participants who have not yet reached 20% • Minimum shipment for Sinovac changed to 20,400 for
population over 1 million and 1,200 for population less than
• This happened to 22 Participants, 20 of whom had benefitted 1 million
from dose donations in advance of Round 6 (the other 2 were
small population participants nearing 20% coverage—) • 2 participants marked to voluntary delay in this round
• As this is likely to be the only Allocation Round with a • 2 participants earmarked for Sinopharm
significant volume of Sinovac and Sinopharm for distribution,
it does not make sense to allocate the Round minimum to • Pro-rata shares for Sinopharm corrected for 3 participants
Participants, given its low potential for impact vis-à-vis the since there was a rounding error before
tremendous efforts associated with introducing another
vaccine in country
67
Eligible Participant Summary
Background – Scenario 1
Participant Scope Criteria Participants (n)
Inclusion
Participant Scope AMC 89
COVAX Facility Participants OP 39
• There are 89 Advance Market Commitment (AMC) and 73 Self
CP 31
Financing (SFP) participants to the COVAX Facility.
Readiness Assessment Team Europe 3
• AMC participant readiness assessments are regularly conducted and Total Inclusion 162
were taken into account for this Round.
Exclusion
Eligibility Criteria
Has not met financial obligations 1
• The following participants were eligible to receive available supplies of
Sinopharm and Sinovac in this Round: All AMC participants; Optional
• CP: 0
Purchaser (OPs) who opted-in for the either or both vaccine deals; Opt outs
Committed Purchasers (CPs) without price cap. • OP: 22
Delay Toggle and Vaccine Preferences
Delay Toggle 26
• In advance of this Allocation Round, COVAX Facility Participants
were reminded of their right to skip the present Round by activating the
Round’s delay toggle on the COVAX Collaboration Platform (CCP) and Not Ready 0
were invited to update their preferences in the CCP. 20% population coverage (or
29
• Participants also received targeted communications asking them to requested) reached
express their preference for receiving either Sinopharm, Sinovac, or
indifference to the two products. These inputs were accounted for when
Other Combinations Not Allowed 1
making the allocation. Total Exclusion 79
Several Participants were excluded for more than one reason, but for the table on this slide, only one reason was selected in the following hierarchy to avoid double-counting: coverage achieved, delay toggle, OP who
8
opted out, has not met financial obligations, other. The full exclusion report is included as a tab on the Round output spreadsheet.Descriptive Statistics Summary of the Participants, Their Allocation and Total Coverage
Scenario 1
9Overview of the Total Round 6 Allocation on top of Previous Allocations
(All Participants with Allocations) – Scenario 1
10Distribution Proposal & Shipment Considerations – Scenario 1
COVAX Allocation Round 6
Distribution Proposal
• The average population coverage across all 83 participants achieved with doses allocated in Round 6 is
1.68%. The average cumulative coverage from Rounds 1 to 6 for these same 83 participants is 7.61%.
• After Round 6, the average cumulative coverage from Rounds 1 to 6 for all 153 participants who have received an allocation from
COVAX in any round is 10.21%. The median cumulative coverage for these same 153 participants is 5.72%.
• In alignment with the standard reallocation process, Participants will be notified that they are allotted a six-week period to clear all
post-allocation preparedness checks following notification of the Round’s outcome.
• Subsequent changes to Participants’ total coverage from this Round resulting from the standard reallocation process will be
communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal
once completed.
Shipment Considerations
• Normally, to facilitate logistics planning, a prioritized shipping order is recommended for distribution of doses allocated in a
Round. In developing this order, a stratified randomization approach was adopted in past Rounds to ensure that all participants
are given an equal chance in the initial shipment queue.
• For Round 6, a decision was taken to inform the sequencing of shipments based on participants’ overall achieved population
coverage (from all sources of supply) and their epidemiological situation.
• The Facility recommends that, closer to the date of the planned shipment, participants’ absorption capacity be assessed to
ensure all the planned quantities can be used by participants within the vaccines’ expiry dates.
1112
Eligible Participant Summary
Background – Scenario 2
Participant Scope Criteria Participants (n)
Inclusion
Participant Scope AMC 89
COVAX Facility Participants OP 39
• There are 89 Advance Market Commitment (AMC) and 73 Self
CP 31
Financing (SFP) participants to the COVAX Facility.
Readiness Assessment Team Europe 3
• AMC participant readiness assessments are regularly conducted and Total Inclusion 162
were taken into account for this Round.
Exclusion
Eligibility Criteria
Has not met financial obligations 1
• The following participants were eligible to receive available supplies of
Sinopharm and Sinovac in this Round: All AMC participants; Optional
• CP: 0
Purchaser (OPs) who opted-in for the either or both vaccine deals; Opt outs
Committed Purchasers (CPs) without price cap. • OP: 22
Delay Toggle and Vaccine Preferences
Delay Toggle 27
• In advance of this Allocation Round, COVAX Facility Participants
were reminded of their right to skip the present Round by activating the
Round’s delay toggle on the COVAX Collaboration Platform (CCP) and Received 0 Allocation 22
were invited to update their preferences in the CCP. 20% population coverage (or
29
• Participants also received targeted communications asking them to requested) reached
express their preference for receiving either Sinopharm, Sinovac, or
indifference to the two products. These inputs were accounted for when
Other Combinations Not Allowed 1
making the allocation. Total Exclusion 102
Several Participants were excluded for more than one reason, but for the table on this slide, only one reason was selected in the following hierarchy to avoid double-counting: coverage achieved, delay toggle, OP who
13
opted out, has not met financial obligations, other. The full exclusion report is included as a tab on the Round output spreadsheet.Descriptive Statistics Summary of the Participants, Their Allocation and Total Coverage
Scenario 2
14Overview of the Total Round 6 Allocation on top of Previous Allocations
(All Participants with Allocations) – Scenario 2
15Distribution Proposal & Shipment Considerations – Scenario 2
COVAX Allocation Round 6
Distribution Proposal
• The average population coverage across all 83 participants achieved with doses allocated in Round 6 is
1.76%. The average cumulative coverage from Rounds 1 to 6 for these same 60 participants is 5.58 %.
• After Round 6, the average cumulative coverage from Rounds 1 to 6 for all 153 participants who have received an allocation from
COVAX in any round is 9.98%. The median cumulative coverage for these same 153 participants is 5.78%.
• In alignment with the standard reallocation process, Participants will be notified that they are allotted a six-week period to clear all
post-allocation preparedness checks following notification of the Round’s outcome.
• Subsequent changes to Participants’ total coverage from this Round resulting from the standard reallocation process will be
communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal
once completed.
Shipment Considerations
• Normally, to facilitate logistics planning, a prioritized shipping order is recommended for distribution of doses allocated in a
Round. In developing this order, a stratified randomization approach was adopted in past Rounds to ensure that all participants
are given an equal chance in the initial shipment queue.
• For Round 6, a decision was taken to inform the sequencing of shipments based on participants’ overall achieved population
coverage (from all sources of supply) and their epidemiological situation.
• The Facility recommends that, closer to the date of the planned shipment, participants’ absorption capacity be assessed to
ensure all the planned quantities can be used by participants within the vaccines’ expiry dates.
16Conclusion & Signatures
COVAX Allocation Round 6
Conclusion
The IAVG unanimously validates the allocation proposal contained in scenario 2.
Next Steps Signatures
Signature Assistant Director General, Signature Managing Director,
Process Step Date Access to Medicines and Health Office of the COVAX Facility, Gavi
Products, WHO
JAT sends allocation proposal to IAVG 21 July 2021
Mariângela SIMÃO/Bruce AYLWARD Aurélia NGUYEN
IAVG Decision Meeting 23 July 2021
On date: On date:
JAT notifies the Office of the COVAX Facility and
23 July 2021
the Procurement Coordinator
WHO DDG communicates to Allocation
26 July 2021
Leadership (Dr SIMAO/Dr AYLWARD)/JAT
IAVG report sent to the WHO DDG 28 July 2021
17Thank you
19
Overview of the Total Round 6 Allocation on top of Previous Allocations (Only
Participants with Allocations This Round)
20Overview of the Total Round 6 Allocation on top of Previous Allocations
(All Participants with Allocations)
21Background material
22Overview of Allocations to Date
Allocation Approval Doses Allocated
Allocation Round Product Name WHO EUL Date Doses Allocated Description
Date Adjusted*
Pfizer BioNTech –
COVAX-1 30 Dec 2021 29 Jan 2021 1,200,420 1,200,420 Pfizer Feb-Mar 2021
Comirnaty
23 Feb 2021, AZ and SII-AZ Jan-May
COVAX-2 AstraZeneca – Vaxzevria 15 Feb 2021 75,996,000 75,412,800
IAVG 2021
23 Feb 2021, AZ and SII-AZ Jan-May
COVAX-2 SII – Covishield 15 Feb 2021 161,472,000 29,790,600
IAVG 2021
Pfizer BioNTech – 15 Mar 2021,
COVAX-3 30 Dec 2021 14,109,030 14,109,030 Pfizer Apr-Jun 2021
Comirnaty IAVG
AZ to cover
COVAX-4 AstraZeneca – Vaxzevria 15 Feb 2021 8 June 2021 17,366,400 17,366,400 COVAX Round 2 SII
shortage
COVAX-5 Pfizer BioNTech – 30 Dec 2021 15 July 2021, 72,190,170 67,205,970 Pfizer July-September
Comirnaty IAVG 2021
Includes dose donations
from: France, Japan,
Donations distributed as
Dose Donations AstraZeneca – Vaxzevria 15 Feb 2021 21,820,690 21,820,690 New Zealand, Norway,
of 19 July 2021
Spain, Sweden, and the
United Kingdom
Donations distributed as
Dose Donations Moderna – mRNA-1273 30 April 2021 50,151,200 50,151,200
of 19 July 2021
Part of a United States
Pfizer BioNTech – Donations distributed as
Dose Donations 30 Dec 2021 12,737,790 12,737,790 Government dose
Comirnaty of 19 July 2021
donation initiative
Donations distributed as
Dose Donations Janssen - Ad26.COV 2-S 12 March 2021 22,150,150 22,150,150
of 19 July 2021
Totals 449,193,850 311,945,050
Adjustments refer to post-allocation changes to Participants’ originally allocated doses from a given round. Adjustments are made either through the reallocation of allocated doses or redeployment of allocated doses already
in country. Both reallocation and redeployment are important to ensure no idle doses, when a COVAX Participant is not prepared or not willing to receive/use doses allocated or delivered. In addition, adjustments have been
made to reflect the delays experienced by those Participants originally allocated SII-AZ doses in Round 2, to ensure these delayed volumes do not count towards official allocated amounts and to ensure equity of coverage
23
across Facility Participants.Overview of Dose Donations to Date
Donor Product Doses Donated
France AstraZeneca – Vaxzevria 4,463,200
Japan AstraZeneca – Vaxzevria 11,151,170
New Zealand AstraZeneca – Vaxzevria 211,200
Norway AstraZeneca – Vaxzevria 530,960
Spain AstraZeneca – Vaxzevria 756,480
Sweden AstraZeneca – Vaxzevria 1,027,200
United Kingdom AstraZeneca – Vaxzevria 3,680,480
United States of America Moderna – mRNA-1273 50,151,200
United States of America Pfizer BioNTech – Comirnaty 12,737,790
United States of America Janssen - Ad26.COV 2-S 22,150,150
Totals 106,859,830
24Overview of Dose Donations to Date
25Scenario 1 vs. Scenario 2: In scenario 2, for the mean increase in allocation across all
60 participants who received an allocation is 0.06%
26You can also read
